Drug intelligence / Profile preview

PP242

Development stage
Preclinical
Modality
Small Molecules
Administration
In Vitro (laboratory Research Use Only)
01

Overview

PP242 is a potent, selective and ATP-competitive small molecule inhibitor of the mammalian target of rapamycin (mTOR), a serine/threonine kinase that regulates cell growth. It inhibits both mTOR complexes, mTORC1 and mTORC2, with IC50 values of 0.03 µM and 0.058 µM, respectively, and is notably more effective at inhibiting mTORC1 than rapamycin. PP242 blocks the phosphorylation of Akt at S473, suppressing mTOR activation and cap-dependent translation. Besides mTOR, PP242 inhibits kinases JAK2, PRKCA, PRKCB (PKCβ I/II), DNAPK, EGFR, and VEGFR2 at higher concentrations, but its principal target is mTOR. It is primarily used in cancer research and cell signaling pathways as a research tool and is not approved for clinical or diagnostic use[1][2][3][9][10].

Other names
2-(4-amino-1-isopropyl-1H-pyrazolo[3,4-d]pyrimidin-3-yl)-1H-indol-5-ol
02

Targets

DNA-PK (DNA-dependent protein kinase)EGFR (Epidermal growth factor receptor)JAK2 (Janus kinase 2)PRKCA (Protein kinase C alpha)RET (Rearranged during transfection receptor tyrosine kinase)VEGFR2 (Vascular endothelial growth factor receptor 2)mTOR (Mammalian target of rapamycin kinase)PIK3CA (Phosphoinositide 3-kinase alpha)PIK3CB (Phosphatidylinositol 3-kinase beta subunit)PIK3CG (Phosphatidylinositol 4,5-bisphosphate 3-kinase gamma)PIK3CD (Phosphatidylinositol 3-kinase delta)PRKCB (Protein kinase C beta)

Beyond the preview

Go deeper on PP242.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on PP242.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call